Our previous publications have set-up the diagnosis of these diseases by testing the IL-10 levels in ocular (Costopoulos et al., Ophthalmology 2016) and cerebrospinal fluids (Nguyen-Them L et al., Eur J Cancer 2016). These soluble biomarker quantifications have constituted a breakthrough in the identification of these disorders. We pursue this work by evaluating other soluble biomarkers, like the recently identified prognostic indicators sCD19, CXCL13, and sCD25. We also work on circulating tumor DNA from cerebrospinal and ocular fluids in order to search for clone-specific IG gene rearrangements as well as cancer-associated gene mutations.